PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
November 1, 2025Neuro-OncologyOpen Access

IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

View Full Paper
Ask AI
Bookmark
Share

Authors

BEBenjamin M. EllingsonIMIngo MellinghoffMBMartin J. van den Bent

Discussion

Loading...

Member takes

Overview

Analysis reveals TGR predicts better progression-free survival in glioma patients, suggesting its role as a surrogate endpoint.

Key Points

  • The study aims to evaluate the predictive value of tumor growth rate models on clinical outcomes in glioma patients.
  • Analyzed volumetric data from the Phase 3 INDIGO trial comparing vorasidenib and placebo.
  • Assessed tumor growth using a linear regression model, bi-exponential model, and velocity of diametric expansion.
  • Correlated individual tumor growth rates with progression-free survival and time to next intervention.
  • Voradidenib treatment resulted in significantly lower individual TGRs compared to placebo across all models.
  • Lower individual TGRs correlated with better progression-free survival and time to next intervention outcomes.
  • Multivariate analysis identified treatment type and baseline tumor volume as determinants for reduced individual TGRs.

Cite This Study

Ellingson et al. (2025) studied this question.

synapsesocial.com/papers/69254362c0ce034ddc35822fhttps://doi.org/10.1093/neuonc/noaf201.1178
View Full Paper
Ask AI
Bookmark
Share